MiddleBrook Pharmaceuticals receives FDA OK for drug
Shares of MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) are rocketing this morning after the pharmaceutical company said it received approval from the U.S. Food and Drug Administration for its Moxtag drug for strep throat.
Adults and pediatric patients 12 years and older now only have to take one tablet (775 mg) of Moxtag daily as opposed to taking penicillin four times daily.
MiddleBrook also added that it has agreed to the FDA’s request to develop a version of MOXATAG for pediatric patients younger than 12 years of age with strep throat. The company said it will submit a completed study report and data set within the next five years.
Shares of MiddleBrook (MBRK) soared 188%, or $2.35, to $3.60 at 10:07 a.m. ET. Pharmaceuticals Shares of MiddleBrook Pharmaceuticals have been trading in the range of $1 to $4 for the past 52 weeks.
